2194 studies found for:    paclitaxel
Show Display Options
Rank Status Study
1 Completed Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Stage II Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Drug: docetaxel;   Biological: bevacizumab
2 Active, not recruiting Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Sunitinib
3 Active, not recruiting Study Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: nab-Paclitaxel;   Drug: Paclitaxel
4 Recruiting A Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin With Concurrent Radiation Therapy Followed by Consolidation in Patients With Favorable Prognosis Inoperable Stage IIIA/B NSCLC
Condition: INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER
Interventions: Drug: NAB-PACLITAXEL;   Drug: PACLITAXEL
5 Recruiting Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
Condition: Neoplasms
Interventions: Drug: Carboplatin;   Drug: BIBW 2992;   Drug: Paclitaxel;   Drug: BIBW2992;   Drug: Bevacizumab
6 Completed Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
Conditions: Solid Tumor Cancer;   Neoplasms, Breast
Interventions: Drug: Pazopanib;   Drug: Lapatinib;   Drug: paclitaxel;   Drug: carboplatin
7 Active, not recruiting Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Placebo
8 Active, not recruiting Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: HEAD & NECK Cancer
Intervention: Other: Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)
9 Not yet recruiting Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Condition: Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Abraxane (Induction);   Drug: Carboplatin (Induction);   Drug: Abraxane (Maintenance);   Other: Best Supportive Care (Maintenance)
10 Completed Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Condition: Occult Primary
Interventions: Drug: belinostat, carboplatin, paclitaxel;   Drug: carboplatin, paclitaxel
11 Recruiting Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: nab-paclitaxel
12 Recruiting Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Condition: Resectable Pancreatic Adenocarcinoma
Interventions: Drug: LDE-225;   Drug: Gemcitabine;   Drug: nab-paclitaxel
13 Recruiting BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: BKM120 days 1 - 21 plus paclitaxel + carboplatin;   Drug: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin;   Drug: BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)
14 Active, not recruiting Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Recurrent Esophageal Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage IV Esophageal Cancer
Interventions: Biological: cixutumumab;   Drug: paclitaxel
15 Completed Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Stage II Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Procedure: adjuvant therapy;   Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab
16 Terminated
Has Results
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Conditions: Breast Neoplasms;   Neoplasm Metastasis
Interventions: Drug: ABI-007 (Abraxane);   Drug: bevacizumab
17 Recruiting Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
18 Recruiting PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: PEGPH20+nab-paclitaxel+gemcitabine;   Drug: nab-paclitaxel + gemcitabine
19 Completed
Has Results
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Adriamycin and Cytoxan (AC);   Drug: ABI-007;   Drug: Taxol;   Drug: Bevacizumab;   Drug: pegfilgrastim
20 Completed
Has Results
Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
Condition: Neoplasms, Gastrointestinal Tract
Interventions: Drug: Lapatinib;   Drug: Paclitaxel

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years